Protease inhibitors: silver bullets for chronic hepatitis C infection?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22383557.
- Also identified by DOI 10.3949/ccjm.79a.11082.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent trials evaluated the safety and efficacy of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), added to standard care with pegylated interferon and ribavirin, in patients with chronic hepatitis C virus (HCV) infection. These drugs open the door for triple therapy and other new therapies involving combinations of other direct-acting antiviral agents to become the new standard of care for this population.
Medical subject headings
- Hepatitis C
- Oligopeptides
- Proline
- Protease Inhibitors